Duvir Tablet 90 mg+400 mg combines Ledipasvir 90 mg and Sofosbuvir 400 mg, a fixed-dose antiviral therapy for the treatment of chronic hepatitis C virus (HCV) infection. This combination tablet targets HCV genotypes 1, 4, 5, and 6, offering high rates of viral clearance and sustained virologic response (SVR).

Hepatitis C is a viral infection affecting the liver, which can lead to chronic liver disease, fibrosis, cirrhosis, and hepatocellular carcinoma if left untreated. Duvir works by directly inhibiting viral replication, targeting two critical proteins of the hepatitis C virus. Ledipasvir blocks NS5A, a viral protein essential for viral replication and assembly, while Sofosbuvir inhibits NS5B polymerase, preventing the virus from multiplying. This dual mechanism provides a potent antiviral effect, making Duvir a cornerstone in modern HCV therapy.

Duvir offers oral, once-daily dosing, simplifying treatment regimens, improving adherence, and minimizing the risk of viral resistance. It is usually prescribed for 12 weeks, with the treatment duration tailored based on HCV genotype, presence of liver cirrhosis, or previous treatment history.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Duvir Tablet 90 mg+400 mg is indicated for:

• Chronic hepatitis C virus (HCV) infection in adults

• HCV genotypes 1, 4, 5, and 6

• Patients with or without compensated cirrhosis

• Use in treatment-naïve or treatment-experienced patients, as advised by a physician

Key Benefits

• Provides high rates of viral clearance and sustained virologic response

• Once-daily oral dosing improves patient adherence

• Minimizes risk of disease progression to cirrhosis or liver cancer

• Well tolerated with favorable safety profile

• Suitable for combination with other supportive therapies as needed

Mechanism of Action

Duvir combines two direct-acting antiviral agents:

• Ledipasvir (90 mg): An NS5A inhibitor that interferes with viral replication, assembly, and secretion of HCV particles. It prevents the virus from effectively multiplying in liver cells.

• Sofosbuvir (400 mg): A nucleotide analog NS5B polymerase inhibitor that halts RNA polymerase activity, stopping viral RNA replication.

The synergistic action of these agents ensures rapid reduction of viral load and prevents the emergence of resistant viral strains.

Dosage and Administration

• The standard dose is one tablet orally once daily, with or without food.

• Typical treatment duration: 12 weeks, although this may be adjusted based on genotype, liver condition, and prior therapy.

• Patients should adhere strictly to the prescribed regimen to ensure optimal viral clearance.

• Routine monitoring of liver function, HCV RNA levels, and potential drug interactions is recommended.

Precautions

• Use with caution in patients with severe liver impairment or kidney dysfunction.

• Inform the physician of all current medications to prevent drug interactions, particularly with amiodarone, antacids, or proton pump inhibitors.

• Not recommended during pregnancy or breastfeeding unless prescribed after careful evaluation.

• Patients should be screened for hepatitis B virus co-infection before initiating therapy.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Duvir is generally well tolerated, with common side effects including:

• Headache

• Fatigue or weakness

• Nausea or diarrhea

• Insomnia

• Rarely, rash or elevated liver enzymes

Most side effects are mild and transient, resolving without discontinuation of therapy.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.